Regeneron Pharmaceuticals Inc (REGN) : Rhenman Partners Asset Management Ab scooped up 37,500 additional shares in Regeneron Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 49,500 shares of Regeneron Pharmaceuticals Inc which is valued at $21,847,815.Regeneron Pharmaceuticals Inc makes up approximately 3.49% of Rhenman Partners Asset Management Ab’s portfolio.
Other Hedge Funds, Including , Putnam Fl Investment Management Co added REGN to its portfolio by purchasing 14,862 company shares during the most recent quarter which is valued at $6,559,641. Regeneron Pharmaceuticals Inc makes up approx 0.75% of Putnam Fl Investment Management Co’s portfolio.Calamos Advisors boosted its stake in REGN in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 4,063 shares of Regeneron Pharmaceuticals Inc which is valued at $1,686,511. Regeneron Pharmaceuticals Inc makes up approx 0.02% of Calamos Advisors’s portfolio.New Century Investment Management Inc reduced its stake in REGN by selling 122 shares or 4.63% in the most recent quarter. The Hedge Fund company now holds 2,511 shares of REGN which is valued at $982,655. Regeneron Pharmaceuticals Inc makes up approx 0.50% of New Century Investment Management Inc’s portfolio. Harding Loevner Lp added REGN to its portfolio by purchasing 166,140 company shares during the most recent quarter which is valued at $63,389,056. Regeneron Pharmaceuticals Inc makes up approx 0.48% of Harding Loevner Lp’s portfolio. First Manhattan Co added REGN to its portfolio by purchasing 50 company shares during the most recent quarter which is valued at $19,077.
Regeneron Pharmaceuticals Inc closed down -7.97 points or -1.81% at $433.4 with 20,26,865 shares getting traded on Thursday. Post opening the session at $443.29, the shares hit an intraday low of $417.5 and an intraday high of $443.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.